Kuros Biosciences’ MagnetOs Flex Matrix has been cleared by FDA as a bone void filler for use in the posterolateral spine.
MagnetOs Flex is an open matrix bone graft with a fibrillar and flexible structure that optimizes the effect of Kuros’ pro-healing NeedleGrip™ surface technology for more predictable fusion.
The clearance of MagnetOs Flex Matrix is the third new FDA clearance for the MagnetOs product family within the last seven months, and follows existing FDA clearances for the use of MagnetOs Granules, MagnetOs Putty and MagnetOs Easypack Putty in the spine.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “This latest clearance of a MagnetOs product rounds out the MagnetOs product family, giving us solutions to meet user needs in most perioperative surgical scenarios in posterolateral fusion and we are pleased to demonstrate again to our investors our success in achieving our strategic goals. It gives us the chance to de-risk our commercialization plans in the U.S. by targeting spine surgeons who mix their bone graft with bone marrow aspirate. It further also allows us to re-engage with surgeons who have previously indicated they are interested in the science of MagnetOs but have not so far used our products based on their handling properties.”
Kuros Biosciences' MagnetOs Flex Matrix has been cleared by FDA as a bone void filler for use in the posterolateral spine.
MagnetOs Flex is an open matrix bone graft with a fibrillar and flexible structure that optimizes the effect of Kuros’ pro-healing NeedleGrip™ surface technology for more predictable fusion.
The clearance of MagnetOs Flex...
Kuros Biosciences’ MagnetOs Flex Matrix has been cleared by FDA as a bone void filler for use in the posterolateral spine.
MagnetOs Flex is an open matrix bone graft with a fibrillar and flexible structure that optimizes the effect of Kuros’ pro-healing NeedleGrip™ surface technology for more predictable fusion.
The clearance of MagnetOs Flex Matrix is the third new FDA clearance for the MagnetOs product family within the last seven months, and follows existing FDA clearances for the use of MagnetOs Granules, MagnetOs Putty and MagnetOs Easypack Putty in the spine.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “This latest clearance of a MagnetOs product rounds out the MagnetOs product family, giving us solutions to meet user needs in most perioperative surgical scenarios in posterolateral fusion and we are pleased to demonstrate again to our investors our success in achieving our strategic goals. It gives us the chance to de-risk our commercialization plans in the U.S. by targeting spine surgeons who mix their bone graft with bone marrow aspirate. It further also allows us to re-engage with surgeons who have previously indicated they are interested in the science of MagnetOs but have not so far used our products based on their handling properties.”
Copy to clipboard 
